Allinaire Therapeutics LLC, an Indianapolis, IN-based life sciences startup company focusing on novel therapeutics for pulmonary diseases, received a seed funding of undisclosed amount.
Backers included BioCrossroads’ Indiana Seed Fund II; BioMotiv, a biomedical accelerator affiliated with the Harrington Project for Discovery & Development; and Indiana University’s Innovate Indiana Fund.
The company, which has also received grant support from the National Institutes of Health, Small Business Innovation & Research program, will use the funds to advance the development of therapeutics for the treatment of AAT deficiency, COPD and other respiratory disorders, including acute lung injury.
Led by Dr. Matthias Clauss, scientific founder and Associate Research Professor of Cellular & Integrative Physiology, Indiana Center for Vascular Biology & Medicine, Indiana University School of Medicine, and Dr. Irina Petrache, scientific founder and chief, Division of Pulmonology, Critical Care and Sleep Medicine, National Jewish Health, Allinaire Therapeutics has identified a novel target to halt the progression of Chronic Obstructive Pulmonary Disease (COPD) and other pulmonary diseases.
Drs. Petrache and Clauss have already demonstrated that a therapeutic antibody against this target has a strong potential as a disease – modifying treatment to slow the progression of COPD.